Oncology Archives - Page 15 of 22

Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: a model based analysis

Authors: V Daniels, K Saxena, C Roberts, S Kothari, S Corman, L Yao, L Niccolai Published: Vaccines, 2021 View publication Abstract The coronavirus disease 2019 (COVID-19) pandemic has significantly affected utilization of...

Economic value of lost productivity attributable to human papillomavirus cancer mortality in the United States

Authors: M Priyadarshini, V S Prabhu, S J Snedecor, S Corman, B J Kuter, C Nwankwo, D Chirovsky, E Myers Published: Frontiers in Public Health, 2021 View publication Objectives To estimate years...

Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States

Authors: C L Simons, D Malone, M Wang, G A Maglinte, T Inocencio, S W Wade, C Bennison, B Shah Published: Journal of Medical Economics, 2021 View publication Aims The objective of...

What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell carcinoma

Authors: S L Klijn, E Fenwick, S Kroep, K Johannesen, B Malcolm, M Kurt, C Kiff, J Borrill Published: PharmacoEconomics, 2020 View publication Background The immuno-oncologic (IO) mechanism of action may lead...

Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: a large retrospective cohort analysis

Authors: N Joshi, H Kale, S Corman, T Wert, K Hill, A M Zeidan Published: Clinical Lymphoma Myeloma Leukemia, 2020 View publication Background Suboptimal use of hypomethylating agents (HMAs) among higher-risk myelodysplastic...

Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis

Authors: S Corman, N Joshi, T Wert, H Kale, K Hill, A M Zeidan Published: Clinical Lymphoma, Myeloma Leukemia, 2020 View publication Background Recent data suggest significant underutilization of hypomethylating agents (HMAs)...

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review

Authors: R Hajek, S Gonzales-McQuire, Z Szabo, M Delforge, L DeCosta, MS Raab, W Bouwmeester, M Campioni, A Briggs Published: BMJ Open, 2020 View publication Objectives and design A novel risk stratification...

Medical oncology referral and systemic therapy of patients with advanced stage urothelial carcinoma

Authors: A Abdalla, C Johnson, Y Doleh, R Shenolikar, M F Botteman, A Hussain Published: Journal of Comparitive Effectiveness Research, 2020 View publication Aim To understand physician visit patterns among patients with...

Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment

Authors: S Srinivas, A F Mohamed, S Appukkuttan, M Botteman, X Ng, N Joshi, J Tsai, J Fang, A R Waldeck, S J Simmons Published: Cancer Medicine, 2020 View publication Background Recently...

News